{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:28:24Z","timestamp":1787236104811,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jid.2023.10.022","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T15:11:50Z","timestamp":1700493110000},"page":"794-801.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic\u2013Pharmacodynamic Modeling"],"prefix":"10.1016","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6664-2490","authenticated-orcid":false,"given":"Astrid","family":"van Huizen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3000-6828","authenticated-orcid":false,"given":"Paul","family":"Bank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-6116","authenticated-orcid":false,"given":"Gayle","family":"van der Kraaij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-4554","authenticated-orcid":false,"given":"Annelie","family":"Musters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7074-7060","authenticated-orcid":false,"given":"Celine","family":"Busard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6522-7220","authenticated-orcid":false,"given":"Stef","family":"Menting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9600-1312","authenticated-orcid":false,"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7570-473X","authenticated-orcid":false,"given":"Annick","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-7899","authenticated-orcid":false,"given":"Martijn","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-660X","authenticated-orcid":false,"given":"Errol","family":"Prens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5303-9310","authenticated-orcid":false,"given":"Jo","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-2673","authenticated-orcid":false,"given":"Juul","family":"van den Reek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3872-5704","authenticated-orcid":false,"given":"Elke","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8401-0879","authenticated-orcid":false,"given":"Ron","family":"Math\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-2863","authenticated-orcid":false,"given":"Phyllis","family":"Spuls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2023.10.022_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jid.2023.10.022_bib2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.semarthrit.2005.01.005","article-title":"Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles","volume":"34","author":"Anderson","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jid.2023.10.022_bib3","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1080\/09546634.2022.2043546","article-title":"Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial","volume":"33","author":"Atalay","year":"2022","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2023.10.022_bib4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/psp4.12404","article-title":"NONMEM tutorial Part I: Description of commands and options, with simple examples of population analysis","volume":"8","author":"Bauer","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jid.2023.10.022_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/FTD.0000000000000494","article-title":"Explaining interpatient variability in adalimumab pharmacokinetics in patients with Crohn's disease","volume":"40","author":"Berends","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jid.2023.10.022_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13063-017-1777-y","article-title":"Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial","volume":"18","author":"Busard","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.jid.2023.10.022_bib7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00228-009-0782-9","article-title":"The role of population PK-PD modelling in paediatric clinical research","volume":"67","author":"De Cock","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jid.2023.10.022_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","article-title":"The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases","volume":"53","author":"Jani","year":"2014","journal-title":"Rheumatol (Oxford)"},{"key":"10.1016\/j.jid.2023.10.022_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/jid.2014.295","article-title":"Immunogenicity of biotherapy used in psoriasis: the science behind the scenes","volume":"135","author":"Jullien","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.10.022_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/bdd.2134","article-title":"Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease","volume":"39","author":"Kimura","year":"2018","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.jid.2023.10.022_bib11","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201544","article-title":"Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner","volume":"71","author":"Krieckaert","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2023.10.022_bib12","first-page":"431","article-title":"Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate","volume":"35","author":"l'Ami","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jid.2023.10.022_bib13","series-title":"Pharmacodynamics. Treasure Island","author":"Marino","year":"2023"},{"key":"10.1016\/j.jid.2023.10.022_bib14","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.12869","article-title":"Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn\u2019s disease","volume":"40","author":"Mazor","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jid.2023.10.022_bib15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamadermatol.2013.8347","article-title":"Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up","volume":"150","author":"Menting","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2023.10.022_bib16","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1038\/psp.2012.4","article-title":"Basic concepts in population modeling, simulation, and model-based drug development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jid.2023.10.022_bib17","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/psp.2013.14","article-title":"Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods","volume":"2","author":"Mould","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jid.2023.10.022_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40262-016-0502-4","article-title":"Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa","volume":"56","author":"Nader","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jid.2023.10.022_bib19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/cts.12725","article-title":"Using real-world data to guide ustekinumab dosing strategies for psoriasis: a prospective pharmacokinetic-pharmacodynamic study","volume":"13","author":"Pan","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jid.2023.10.022_bib20","first-page":"821","article-title":"Combination of adalimumab with traditional systemic antipsoriatic drugs - a report of 39 cases","volume":"10","author":"Philipp","year":"2012","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.jid.2023.10.022_bib21","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/pharmaceutics14030654","article-title":"Impact of pharmacokinetic and pharmacodynamic properties of monoclonal antibodies in the management of psoriasis","volume":"14","author":"Rodr\u00edguez-Fern\u00e1ndez","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jid.2023.10.022_bib23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF03261932","article-title":"Fundamentals of population pharmacokinetic modelling: validation methods","volume":"51","author":"Sherwin","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jid.2023.10.022_bib24","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/11599970-000000000-00000","article-title":"Local versus systemic anti-tumour necrosis factor-\u03b1 effects of adalimumab in rheumatoid arthritis: pharmacokinetic modelling analysis of interaction between a soluble target and a drug","volume":"51","author":"Stepensky","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jid.2023.10.022_bib25","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bcp.12509","article-title":"Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis","volume":"79","author":"Ternant","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jid.2023.10.022_bib26","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1038\/psp.2013.71","article-title":"Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods","volume":"3","author":"Upton","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jid.2023.10.022_bib27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/09546634.2012.751483","article-title":"Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice","volume":"24","author":"van den Reek","year":"2013","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2023.10.022_bib28","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1016\/j.jid.2022.01.033","article-title":"Adalimumab with methotrexate versus adalimumab monotherapy in psoriasis: first-year results of a single-blind randomized controlled trial","volume":"142","author":"van der Kraaij","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2023.10.022_bib29","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/jdv.19089","article-title":"Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: three-year follow-up data of a single-blind randomized controlled trial","volume":"37","author":"van Huizen","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2023.10.022_bib30","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3389\/fimmu.2020.02042","article-title":"Methotrexate enhances apoptosis of transmembrane TNF-expressing cells treated with anti-TNF agents","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2023.10.022_bib31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human Anti-tumor Necrosis Factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial [published correction appears in Arthritis Rheum 2003;48:855","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2023.10.022_bib32","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0149-2918(03)80164-9","article-title":"Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human Anti-tumor Necrosis Factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study","volume":"25","author":"Weisman","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.jid.2023.10.022_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0b013e328329ed8b","article-title":"Dealing with immunogenicity of BioLogicals: assessment and clinical relevance","volume":"21","author":"Wolbink","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jid.2023.10.022_bib34","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1002\/jcph.380","article-title":"Clinical impact of concomitant immunomodulators on biologic therapy: pharmacokinetics, immunogenicity, efficacy and safety","volume":"55","author":"Xu","year":"2015","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jid.2023.10.022_bib35","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ecco-jcc\/jjw014","article-title":"Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease","volume":"10","author":"Zittan","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.jid.2023.10.022_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-008-9094-4","article-title":"Likelihood based approaches to handling data below the quantification limit using NONMEM VI [published correction appears in J Pharmacokinet Pharmacodyn 2010;37:305\u20138]","volume":"35","author":"Ahn","year":"2008","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jid.2023.10.022_bib37","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/psp4.12611","article-title":"Approaches to handling missing or \"problematic\" pharmacology data: pharmacokinetics","volume":"10","author":"Irby","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23031032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X23031032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T20:20:37Z","timestamp":1717186837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X23031032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0022202X23031032"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2023.10.022","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantifying the Effect of Methotrexate on Adalimumab Response in Psoriasis by Pharmacokinetic\u2013Pharmacodynamic Modeling","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2023.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}